# Safety, Tolerability and Systemic Absorption of Menadione Topical Lotion for Epidermal-Growth-Factor-Receptor (EGFR) Inhibitor-Associated Rash

> **NCT00656786** · PHASE1 · COMPLETED · sponsor: **Spectrum Pharmaceuticals, Inc** · enrollment: 18 (actual)

## Conditions studied

- EGFR Inhibitor-associated Rash

## Interventions

- **DRUG:** Menadione Topical Lotion
- **DRUG:** Menadione Topical Lotion

## Key facts

- **NCT ID:** NCT00656786
- **Lead sponsor:** Spectrum Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04-03
- **Primary completion:** 2009-12-30
- **Final completion:** 2009-12-30
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2020-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00656786

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00656786, "Safety, Tolerability and Systemic Absorption of Menadione Topical Lotion for Epidermal-Growth-Factor-Receptor (EGFR) Inhibitor-Associated Rash". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00656786. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*